CBD Dosage for Beginners - How to Start and Achieve the Best Results?

The first bottle of CBD oil always raises the same question: how many drops. The answer circulating in guides is 5-10 mg per day, but none of them indicate the study from which this number originates. This guide takes a different path: every milligram number you read here is supported by a study or document where it actually appears. You will learn how much cannabidiol was administered in clinical trials on anxiety and epilepsy, what dose the European risk assessment body currently considers temporarily safe in supplements, how to calculate milligrams from your own bottle, and why a meal changes the body’s exposure more than changing the oil concentration. Several popular numbers will disappear along the way because they are not found in the cited sources.

KEY INFORMATION
• The temporary safe dose for CBD supplements is 0.0275 mg per kilogram of body weight per day, about 2 mg daily for a 70 kg person (EFSA NDA Panel, 2026).
• Clinical studies used doses two to three orders of magnitude higher: 400 mg single dose in social anxiety (Crippa et al., 2011), 600 mg single dose (Bergamaschi et al., 2011), 20 mg/kg per day in Dravet syndrome (Devinsky et al., NEJM, 2017). These are doses under medical supervision, not supplement doses.
• No study has established oral or sublingual bioavailability of CBD in humans; the only measured one concerns smoking and is 31% (Millar et al., 2018).
• A fatty meal increased the area under the concentration curve fourfold and the maximum concentration fourteenfold (Birnbaum et al., Epilepsia, 2019).
• An extract with predominance of CBD increased exposure to omeprazole by 207%, losartan by 77%, and midazolam by 56% (Bansal et al., 2023).

From how many milligrams of CBD should you start?

From the smallest amount you can measure and after consulting with a doctor if you take any medications. The honest answer is this: there is no study that establishes an initial cannabidiol dose for a healthy adult taking a supplement. Numbers circulating in guides come not from literature but from each other.

This is not an excuse but the state of knowledge. A systematic review of CBD pharmacokinetics in humans covered 792 found papers, of which 24 had data suitable for analysis. The authors conclude with a statement about data insufficiency and discrepancies in results despite widespread use of this substance (Millar et al., Frontiers in Pharmacology, 2018). It is difficult to derive a dosing scheme from an evidence base that calls itself incomplete.

Two reference points are firm and worth adhering to simultaneously. The first is the temporary safe dose derived by the European risk assessment panel for supplements: 0.0275 mg per kilogram of body weight per day. The second is doses from clinical studies, counted in hundreds of milligrams, administered under medical supervision in specific diseases. Both are described below because they differ by two to three orders of magnitude, and this difference is the most important information in the entire text.

A practical takeaway at the start: if you are looking for a number to start with, take the one from the risk assessment, not the clinical study. Clinical studies answered whether CBD works in disease, not how much can be safely taken daily without medical indication.

What dose of CBD is currently considered safe in supplements?

Temporarily 0.0275 mg per kilogram of body weight per day, about 2 mg daily for a 70 kg person. This value was derived by the benchmark dose method from subchronic studies compliant with good laboratory practice, applying an uncertainty factor of 400 (EFSA NDA Panel, updated opinion on CBD safety as novel food, 2026).

This number has a narrow scope and must be known. It applies exclusively to supplements with cannabidiol purity of at least 98%, without nanoparticles, produced by a process recognized as safe, and with excluded genotoxicity. It does not cover full-spectrum oils, gummies, or cosmetics, as these forms do not meet the above condition.

The panel also explicitly states what it could not establish. CBD safety cannot be determined for people under 25 years old, pregnant and breastfeeding women, and people taking medications simultaneously. The gaps indicated in the 2022 opinion have not been closed, and new studies have methodological limitations: non-standardized protocols, short observation times, and concomitant treatments.

Animal studies noted consistent liver toxicity, with liver mass and histopathological changes being the most sensitive endpoints. In humans, hepatotoxic potential was described, especially with concomitant medication. Cannabidiol crosses the placenta and accumulates systemically, and prenatal exposure showed long-term sex-dependent neurodevelopmental effects. Immunotoxicity was not studied in any reviewed research.

Safety assessment is not the same as market authorization. The opinion does not authorize CBD as novel food and does not change the ingredient’s status; a sanitary notification filed by the seller also does not do this.

What doses of CBD were administered in clinical studies?

From several hundred milligrams single dose to 20 mg per kilogram of body weight per day, always under medical supervision and always for a specific indication. The table below contains only doses mentioned in the abstracts of cited papers. It is not a dosing table for readers and should not be read as such.

Two things in this table are more important than the numbers themselves. First, three of the four entries are single doses or therapeutic doses in severe disease, not daily supplementation schemes. Second, Shannon’s work is cited in guides as the source of a 25 mg evening dose, but the abstract does not contain this number at all. The authors conclude that controlled studies are needed. More about evidence on cannabidiol’s effect on sleep is collected in the text about whether CBD helps with sleep.

What is the “start low, go slow” principle?

It means changing one thing at a time and giving it time before evaluating the result. It is a rule of conduct, not a dose, and that is why it can be described honestly without relying on a number that no one has measured. Titration makes sense because pharmacokinetic data for cannabidiol are incomplete and inconsistent between studies, as Millar and colleagues’ review states plainly.

1. Set the starting point together with a doctor or pharmacist, especially if you take medications regularly. This is the only stage that cannot be replaced by reading.
2. Maintain the same product form, time, and method of administration throughout the observation period. Changing two things at once makes the result meaningless.
3. Record daily what you want to improve on a simple numerical scale. Without recording, the assessment after two weeks is a memory, not a measurement.
4. Do not change anything for a week. The effect of a single dose is visible within hours, but in chronic conditions, a month’s result is formed from the whole month.
5. Stop at the amount where you observe improvement and do not increase it for certainty. Higher exposure means higher risk of side effects, which we describe later.

Note that the logic of gradual increase does not say where the ceiling lies. Today it is set on one side by the temporary safe dose from the risk assessment and on the other by the list of contraindications and interactions. A guide that provides a titration scheme but mentions neither gives you half the instructions.

How to calculate milligrams of CBD from your own bottle?

With three steps. The only thing you must take on faith is the declared cannabidiol content on the label. First, calculate how many milligrams are in the bottle, then how many drops come from it, and finally divide one by the other. Only then do you know how much you measure.

The second step is the one guides are silent about, and it determines the result. The number of drops per milliliter depends on the dropper diameter, oil viscosity, and temperature, so a value copied from the internet may differ from reality by several tens of percent. Measure it once: drop one milliliter into a syringe or measuring cup, count the drops, and only then calculate further.

The same calculation works for any concentration: with 10% oil in a 10 ml bottle, you get 1000 mg and twice as much per drop as with 5%. The stronger the oil, the less liquid under the tongue, but also the harder it is to measure a small amount. A step-by-step variant of these calculations, including conversion to servings, is in the guide on how to choose a CBD dose in drops and milligrams.

A separate note about the label. A certificate of analysis from a specific batch is the only document linking the number on the bottle to its content. Without it, all the above calculations rely on a declaration that no one has verified, and an error at the starting point carries over to every subsequent dose.

Does the form of administration change the dose?

It does, and significantly, but no one has measured the scale of this change in humans except for one route. A systematic review of cannabidiol pharmacokinetics reports an absolute bioavailability of 31% after smoking and states plainly that no other study has attempted to determine it for other routes in humans, despite availability of intravenous forms (Millar et al., Frontiers in Pharmacology, 2018).

This means that bioavailability tables with numbers like 13-19% for sublingual and 4-12% for oral, repeated in Polish guides for years, have no support in the source they cite. The direction of difference is real, but the magnitude is not established.

What the review really provides and what can be used: half-life from 1.4 to 10.9 hours after oral-mucosal aerosol, 2 to 5 days with chronic oral administration, 24 hours after intravenous administration, and 31 hours after smoking. Maximum concentration and area under the curve increase with dose and are reached faster after smoking and inhalation than oral administration. Time to maximum concentration ranges from zero to four hours.

The practical consequence is simple and does not require percentages. The same number of milligrams measured from oil, eaten in a gummy, or vaporized will produce three different concentration-time profiles, so comparing them directly makes no sense. The mechanism by which the swallowed form loses the most is described separately in the post about the first-pass effect.

How long does it take to feel the effect of CBD?

To appear in the blood from several minutes to four hours, and much longer to assess the effect in chronic conditions. The first of these values is measured: time to maximum concentration ranges from zero to four hours and is shorter after smoking and inhalation than oral administration (Millar et al., Frontiers in Pharmacology, 2018).

The second is much less certain, and guides provide timelines not found in any study. The closest indication is a retrospective review of psychiatric clinic patient charts: anxiety decreased in the first month in 79.2% of people and remained at a reduced level, while sleep improved in the first month in 66.7% but fluctuated in subsequent months (Shannon et al., The Permanente Journal, 2019).

Note the difference between the two results from one study, as it usually disappears in abstracts. Anxiety improvement was stable, sleep improvement was not. This is exactly the kind of detail that determines whether after two months you conclude something stopped working or never worked.

Shannon’s review is a retrospective study without a control group, so it does not separate the substance effect from the effect of time passing and expectations. The authors state this themselves in the conclusion. Treat a month as a reasonable observation horizon, not a promise of outcome.

Where does individual variability in response to CBD come from?

Mostly from what you have in your stomach. The study included eight adult patients with drug-resistant epilepsy, each receiving a single dose of pure cannabidiol in a capsule twice: once fasting, once after a high-fat meal of 840-860 kilocalories. Maximum concentration was on average fourteen times higher after the meal, and area under the curve four times higher (Birnbaum et al., Epilepsia, 2019).

Confidence intervals show how large the variability is among people: the 90% interval for the maximum concentration ratio ranged from 7.47 to 31.86, and for the area under the curve from 3.42 to 7.82. In other words, the meal effect alone varies from sevenfold to thirtyfold for maximum concentration and from threefold to eightfold for area under the curve. The same number of milligrams measured from the bottle thus means different body exposure depending on intake circumstances.

The pharmacokinetic review confirms the direction independently: maximum concentration increases in the fed state and in lipid forms. Sellers rarely mention this, although it is the cheapest way to change real exposure without reaching for a stronger product.

Other sources of variability are less studied. Cannabidiol is metabolized by liver enzymes whose activity varies among people, and the European panel assessment states plainly that bioavailability depends on the carrier matrix and food intake. Body weight, sex, and microbiome composition are mentioned in popular texts but no data in the cited works allow assigning them a specific magnitude.

What side effects does CBD cause?

Most often fatigue and diarrhea, plus changes in appetite or body weight. This is the result of a literature review on cannabidiol safety, which confirmed a favorable profile in humans but also indicated still unexplored areas (Iffland and Grotenhermen, Cannabis and Cannabinoid Research, 2017).

A second review, based on information about registered products, is more cautious. Nearly half of CBD users experienced adverse effects, with frequency generally dose-dependent. Most often reported were increased transaminase activity, sedation, sleep disturbances, infections, and anemia (Brown and Winterstein, Journal of Clinical Medicine, 2019).

A clinical study in Dravet syndrome lists events occurring more frequently than in the placebo group: diarrhea, vomiting, fatigue, fever, drowsiness, and abnormal liver function tests. The cannabidiol group also had more withdrawals from the study (Devinsky et al., New England Journal of Medicine, 2017). This concerns a dose of 20 mg per kilogram of body weight, many times higher than supplement doses.

The liver appears in all three sources and is a signal not to be dismissed. The European risk assessment panel noted consistent liver toxicity in animal studies and hepatotoxic potential in humans, especially with concomitant medication. If persistent fatigue, nausea, or discomfort in the right upper abdomen appear after starting the supplement, it is a reason to contact a doctor, not to change the brand.

What are CBD interactions with medications?

Significant and measured in humans. Eighteen healthy adults received alternately a cookie with a CBD-predominant extract (640 mg cannabidiol and 20 mg delta-9-THC), a cookie with a THC-predominant extract, or placebo, followed by a set of drugs probing specific liver enzymes (Bansal et al., Clinical Pharmacology and Therapeutics, 2023).

Two conclusions from this table contradict what guides repeat. First, cannabidiol, not delta-9-THC, is responsible for enzyme inhibition: the cookie with THC alone did not inhibit any of the tested enzymes. Second, CYP2D6 remained unaffected, so the statement about CBD inhibiting this enzyme, present in many Polish texts, is not supported by this measurement.

Brown and Winterstein’s review adds a mechanism outside the liver: cannabidiol also affects P-glycoprotein involved in drug excretion, so the potential for interactions with commonly used drugs is high. The authors recommend considering dose reduction of substrate drugs, monitoring adverse effects, and seeking alternative therapies, especially in patients with multiple conditions. This recommendation is directed to doctors, not patients.

When not to use CBD?

In three situations where the European risk assessment panel could not establish safety: people under 25 years old, pregnant and breastfeeding women, and people taking medications simultaneously. This is not a cautious editorial formula but a conclusion stated explicitly in the opinion.

The age limit of 25 surprises many readers because national product descriptions usually say eighteen. It results from lack of data on cannabidiol’s effect on the developing nervous system, not from a separate regulation. The law does not prohibit selling supplements to a twenty-year-old; the risk assessment only states that no one has shown it is safe.

Pregnancy and lactation have additional mechanistic justification. Cannabidiol crosses the placenta and accumulates systemically, and prenatal exposure showed long-term sex-dependent neurodevelopmental effects. This means more than the usual “lack of data” and is why it is here, not in a footnote.

Additionally, situations requiring consultation with a doctor before starting, not after: active liver disease, planned surgery, taking drugs metabolized by enzymes listed in the previous section, and psychiatric or neurological treatment. No prescribed medication should be discontinued independently in favor of a supplement.

What to do if CBD does not work?

First, check if the question is well posed. Lack of effect after a week does not mean the same as lack of effect after two months of observation with recording, and without recording, distinguishing one from the other is impossible. Before changing the product, close this issue.

Second, consider intake circumstances. Since a meal alone can change exposure several times, and variability among people reaches several tens of times, taking on an empty stomach and after a fatty meal are two different experiments. Before concluding the substance does not work, check if it even reaches you.

Third, product quality. Without a certificate of analysis from the batch, you have no basis to assume the bottle contains as much cannabidiol as the label declares, and all your calculations rely on that declaration.

A popular advice to switch to a full-spectrum product is based on the entourage effect hypothesis. The author of the paper cited in this context formulates it conditionally: synergy of phytocannabinoids and terpenoids, “if proven,” increases the chance of new therapeutic products, and the review proposes only methods to study it (Russo, British Journal of Pharmacology, 2011). Changing the product form is thus an acceptable experiment but not a step based on evidence. How to choose the first product and form is described in the guide on first CBD purchases.

What is the legal status of CBD in Poland?

Cannabidiol is not listed in any controlled substance schedules, and industrial hemp products are legal in Poland. The threshold for these hemp plants is 0.3% on a dry weight basis, but it is calculated as the sum of delta-9-THC and tetrahydrocannabinolic acid (THCA), rounded to one decimal place. This difference changes the laboratory test result because the fresh raw material predominates in the acid form.

The basis is Article 4 point 5 of the Act of July 29, 2005, on Counteracting Drug Addiction (consolidated text Journal of Laws 2023 item 1939), as amended by the Act of March 24, 2022 (Journal of Laws 2022 item 763), effective from May 7, 2022. The previous value of 0.20%, still repeated in product descriptions, is historical. The national threshold corresponds to the EU threshold but does not derive from it: these are two separate regulations with the same numerical value.

A cannabidiol supplement is not a medicine, and the seller cannot assign it therapeutic effects. A sanitary notification filed when introducing the product to the market is not an authorization of novel food and does not change the ingredient’s status. Pharmaceutical raw material in the form of cannabis other than industrial hemp is a completely different track: it is dispensed on prescription based on the Act of July 7, 2017 (Journal of Laws 2017 item 1458), effective from November 1, 2017.

Separately about driving, because this is where guides can be dangerous. There is no regulation allowing driving after a product containing any amount of THC. Driving under the influence of an intoxicating substance is a crime under Article 178a § 1 of the Penal Code, punishable by imprisonment up to 3 years, and being under the influence is an offense under Article 87 § 1 of the Code of Petty Offenses, punishable by a fine not less than 2500 PLN. Industrial hemp products contain trace amounts of THC, so a positive result cannot be excluded, and its probability cannot be estimated from the label.

How to build your own protocol in four weeks?

Starting with a conversation with a doctor and a notebook, not by choosing oil concentration. Four weeks is a reasonable horizon because the review of patient charts noted changes in anxiety and sleep results precisely in the first month. Below is an action order that does not require a single number taken from nowhere.

Dedicate the first week to the starting point. Write down exactly what you want to improve and how you will measure it, review your medication list for enzymes from the interactions section, check the product’s certificate of analysis, and calculate the content per drop from your own dropper. Determine the amount with a doctor or pharmacist, considering the temporary safe dose from the risk assessment.

Weeks two to four are observation with one setting at a time. Maintain the same product form, time, and method of administration, and a consistent meal schedule, as it accounts for the largest single jump in exposure. Change at most one thing per week and record the result daily, even with a single digit.

After four weeks, you have material for a decision: either you see a change in your records or you do not despite maintained conditions. In the second case, talking to a doctor is more sensible than increasing the amount, especially if the reason for taking the supplement was a symptom requiring diagnosis. Cannabidiol does not replace diagnosis.

Frequently Asked Questions

From how many milligrams of CBD should you start?

There is no study that establishes an initial dose for a healthy adult. The reference point is a temporary safe dose for supplements, amounting to 0.0275 mg per kilogram of body weight per day, which is about 2 mg daily for a 70 kg person (EFSA NDA Panel, 2026). Determine the amount with your doctor, especially if you are on regular medication.

How many drops of 5% oil equal 25 mg of CBD?

A 10 ml bottle of 5% oil contains 500 mg of cannabidiol. Count the drops from one milliliter of your own dropper: if there are 20 drops, the bottle has 200 drops, which means 2.5 mg per drop, and 25 mg equals ten drops. The number of drops depends on the dropper and oil viscosity, so measure it yourself.

Does a fatty meal change the effect of CBD?

It changes the body’s exposure very significantly. After a high-fat meal of 840-860 kilocalories, the maximum concentration was on average fourteen times higher, and the area under the curve four times higher than on an empty stomach (Birnbaum et al., Epilepsia, 2019). The study included eight patients, and variability among them was large.

Can CBD be taken together with medications?

Only after consultation. An extract with a predominance of cannabidiol increased exposure to omeprazole by 207%, losartan by 77%, and midazolam by 56%, without affecting dextromethorphan metabolism (Bansal et al., 2023). The European risk assessment panel has not established the safety of CBD in people taking medications simultaneously.

What are the most common side effects of CBD?

Fatigue, diarrhea, and changes in appetite and body weight (Iffland and Grotenhermen, 2017). A review based on information about registered products reports that nearly half of users experienced adverse effects, most often in the form of increased transaminases, sedation, sleep disturbances, infections, and anemia (Brown and Winterstein, 2019).

Is CBD legal in Poland?

Yes. Cannabidiol is not listed in controlled substance schedules, and products from industrial hemp are legal with a content up to 0.3% calculated as the sum of delta-9-THC and THCA on a dry weight basis, according to Article 4 point 5 of the Act on Counteracting Drug Addiction. The supplement is not a medicine.

Can you drive a car after taking CBD?

There is no regulation allowing driving after a product containing any amount of THC. Driving under the influence of an intoxicating substance is a crime under Article 178a § 1 of the Penal Code, and being under the influence is an offense under Article 87 § 1 of the Code of Petty Offenses. The risk cannot be estimated from the label.

The oils used as examples for calculating milligrams can be found in the oils category; prices range from 65 to 240 PLN as of August 10, 2026.

This article is informational and educational and does not constitute medical advice. Before starting cannabis or CBD for therapeutic purposes, consult a doctor, especially if you take other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-11 · Updated: 2026-08-10